Cargando…

Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach

AIM: To summarise our centre’s experience managing patients with neuroendocrine tumours (NETs) in the first 5 years after the introduction of peptide receptor radionuclide therapy (PRRT) with [(177)Lu]Lu-DOTA-octreotate (LUTATE). The report emphasises aspects of the patient management related to fun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gordon, S., Chan, D. L. H., Bernard, E. J., Eslick, M. E., Willowson, K. P., Roach, P. J., Engel, A. F., Maher, R., Clarke, S. J., Agarwal, V., Yasmin, L., De Silva, M., Mascall, S., Conner, A., Nevell, D., Pavlakis, N., Bailey, D. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374703/ https://www.ncbi.nlm.nih.gov/pubmed/37004598 http://dx.doi.org/10.1007/s00432-023-04706-1

Ejemplares similares

Theranostic SPECT reconstruction for improved resolution: application to radionuclide therapy dosimetry
por: Marquis, H., et al.
Publicado: (2021)

Theranostics: radionuclide imaging and therapy in neuroendocrine tumours
por: Drake, Brent, et al.
Publicado: (2015)

Changing Therapeutic Paradigms: Predicting mCRC Lesion Response to Selective Internal Radionuclide Therapy (SIRT) based on Critical Absorbed Dose Thresholds: A Case Study
por: Willowson, Kathy P, et al.
Publicado: (2017)

Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours
por: Lim, Lisi Elizabeth, et al.
Publicado: (2020)

Individualised dosimetry and safety of SIRT for intrahepatic cholangiocarcinoma
por: Willowson, Kathy P., et al.
Publicado: (2021)

Subcellular Targeting of Theranostic Radionuclides
por: Bavelaar, Bas M., et al.
Publicado: (2018)

Partial volume effect in SPECT & PET imaging and impact on radionuclide dosimetry estimates
por: Marquis, H, et al.
Publicado: (2023)

Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance
por: Chan, David LH, et al.
Publicado: (2017)

Photonuclear production, chemistry, and in vitro evaluation of the theranostic radionuclide (47)Sc
por: Loveless, C. Shaun, et al.
Publicado: (2019)

Cyclotron-based production of the theranostic radionuclides $^{67}$Cu and $^{47}$Sc
por: Pupillo, G, et al.
Publicado: (2019)

Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements
por: Mikolajczak, R., et al.
Publicado: (2021)

Feasibility and accuracy of single time point imaging for renal dosimetry following (177)Lu-DOTATATE (‘Lutate’) therapy
por: Willowson, Kathy P., et al.
Publicado: (2018)

Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
por: D’Huyvetter, Matthias, et al.
Publicado: (2014)

Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs)
por: Öberg, Kjell
Publicado: (2012)

CT-based quantitative SPECT for the radionuclide (201)Tl: experimental validation and a standardized uptake value for brain tumour patients
por: Willowson, Kathy, et al.
Publicado: (2012)

A Comparison of 2D and 3D Kidney Absorbed Dose Measures in Patients Receiving (177)Lu-DOTATATE
por: Willowson, Kathy P, et al.
Publicado: (2018)

Neuroendocrine tumor theranostics
por: Ichikawa, Yasushi, et al.
Publicado: (2022)

Glypican-3 targeted delivery of (89)Zr and (90)Y as a theranostic radionuclide platform for hepatocellular carcinoma
por: Labadie, Kevin P., et al.
Publicado: (2021)

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Zaknun, John J., et al.
Publicado: (2013)

Terbium Radionuclides for Theranostics Applications: A Focus On MEDICIS-PROMED
por: Formento Cavaiera, R, et al.
Publicado: (2020)

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Bodei, L., et al.
Publicado: (2013)

Comparison of radiobiological parameters for (90)Y radionuclide therapy (RNT) and external beam radiotherapy (EBRT) in vitro
por: Gholami, Yaser H., et al.
Publicado: (2018)

Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis
por: Willowson, Kathy P., et al.
Publicado: (2017)

Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET)
por: Wong, Matthew H., et al.
Publicado: (2016)

Nuclides.net: an integrated environment for computations on radionuclides and their radiation
por: Magill, J
Publicado: (2003)

Diagnostic Performance of Theranostic Radionuclides Used in Transarterial Radioembolization for Liver Cancer
por: Li, Rou, et al.
Publicado: (2021)

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
por: Sowa-Staszczak, Anna, et al.
Publicado: (2011)

Survival predictors of (177)Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
por: Swiha, Mina M., et al.
Publicado: (2021)

Radioembolization with (90)Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy
por: Braat, A. J. A. T., et al.
Publicado: (2019)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker
por: Holik, Holis Abdul, et al.
Publicado: (2022)

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
por: Yordanova, Anna, et al.
Publicado: (2020)

Peptide Receptor Radionuclide Therapy Using (177) Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment
por: Kalantarhormozi, Mohammadreza, et al.
Publicado: (2022)

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
por: Fani, Melpomeni, et al.
Publicado: (2017)

Oligonucleotide-Functionalized Gold Nanoparticles for Synchronous Telomerase Inhibition, Radiosensitization, and Delivery of Theranostic Radionuclides
por: Bavelaar, Bas M., et al.
Publicado: (2021)

Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review
por: Hussain, Mazhar, et al.
Publicado: (2023)

In vivo quantification of (177)Lu with planar whole-body and SPECT/CT gamma camera imaging
por: Bailey, Dale L., et al.
Publicado: (2015)

In Vivo Measurement and Characterization of a Novel Formulation of [(177)Lu]-DOTA-Octreotate
por: Bailey, Dale L, et al.
Publicado: (2016)

First In Vivo and Phantom Imaging of Cyclotron-Produced (133)La as a Theranostic Radionuclide for (225)Ac and (135)La
por: Nelson, Bryce J.B., et al.
Publicado: (2022)

Overlooked potential of positrons in cancer therapy
por: Hioki, Takanori, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_igb724oolf9j06cpi3a4892k3r